Posts tagged James Culverhouse
ViroCell Biologics and Great Ormond Street Hospital for Children Announce Partnership to Dislodge Gene and Cell Therapy “Logjam”
Press ReleasesFlorence BuchananCDMO, UK CDMO, ViroCell, ViroCell Biologics, Great Ormond Street Hospital for Children, GOSH, NHS Foundation Trust, lentivirus vector, AAV vectors, cell and gene therapies, gene therapy, cell therapy, Zayed Centre for Research, 1L to 200L batch size, Scientific Advisory Board, John W. Hadden II, Matthew Shaw, CEO at Great Ormond Street Hospital, Great Ormond Street Hospital, Her Highness Sheikha Fatima bint Mubarak, Sheikh Zayed bin Sultan Al Nahyan, Founder of the United Arab Emirates, rare diseases, Great Ormond Street Hospital Children’s Charity, EQ, James Culverhouse, ViroCell Press Release
ViroCell announces new Board appointments
Press ReleasesFlorence BuchananViroCell, CDMO, UK CDMO, J. David Enloe, Martin Pule, Board of Directors, Scientific Advisory Board, gene therapy, cell therapy, viral vectors, viral vector, AAV vectors, lentivirus vectors, CGT, cell and gene therapies, Recro Pharma, Lonza, University College London, University College Hospital, Autolus Therapeutics, John W. Hadden II, Farzin Farzeneh, David Enloe, Dr. Martin Pule, ViroCell Biologics, Truell Conservation Foundation, Edmund Truell, Wellcome Trust, EQ, James Culverhouse, ViroCell Press Release, batch sizes between 1L and 200L, vector design, Daniel Truell
ViroCell, the UK’s first clinical trial focused viral vector manufacturer, announces its official launch
Press ReleasesFlorence BuchananViroCell press release, Truell Conservation Foundation, ViroCell, Edmond Truell, John W. Hadden II, Farzin Farzaneh, Ferid Murad, Evren Alici, Jean-Pierre Bizzari, Mark Lowdell, Peter Harper, Paul G. Richardson, gene therapy, cell therapy, viral vectors, vector design, CDMO, UK CDMO, CGT, Scientfic Advisory Board, 1998 Nobel Prize in Medicine, Karolinska Institutet, French National Cancer Institute (INCa), Celgene, University College London, Royal Free London NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust, Welbeck Health Partners, Dana Farber Cancer Institute, Harvard Medical School, ViroCell Biologics, EQ, James Culverhouse
